Yes yes yes more of this please!!!! Love love love. I agree; I would also like to know if this is just a weightloss effect or GLP1 agonism effect. It would make sense that weightloss would reduce glomerular hyperfiltration. But getting patients to lose weight is not easy so ofcourse this is a huge win. How amazing it is to be a nephro in an era where we have so many drugs that work!
Zaina!!!! Couldn’t agree more about weight loss being tricky for patients and absolutely living so many nephrology drugs - the guidelines get outdated quickly. Exciting times. Ps I would absolutely love to see your version of journal club idol! :) x
Is it just semaglutide or is it a class effect, tirezepatide leads to more weight loss 15% vs 12%, can we substitute mounjaro for ozempic. Also the other question comes in regards to the funding. I strongly doubt Medicare is gonna pay for a weight loss drug in a non T2DM setting (seeing they refused to publicly fund wegovy/zepbound)
Great work
More journal club for nephrology
Yes yes yes more of this please!!!! Love love love.
I agree; I would also like to know if this is just a weightloss effect or GLP1 agonism effect. It would make sense that weightloss would reduce glomerular hyperfiltration. But getting patients to lose weight is not easy so ofcourse this is a huge win. How amazing it is to be a nephro in an era where we have so many drugs that work!
Zaina!!!! Couldn’t agree more about weight loss being tricky for patients and absolutely living so many nephrology drugs - the guidelines get outdated quickly. Exciting times. Ps I would absolutely love to see your version of journal club idol! :) x
Nice animations 😊
Fantastic as usual
Ahmed…you remain one of my favourite humans!
@kristeenbarker Thanks, you as well
have they done a subgroup analysis of people who where not overweight to see if they still maintained benefit ?
Such a great question. I don’t think they did that analysis in the paper at least but could be more subgroup analyses to come.
Great. Yes for me.
Yay!
Yes
Is it just semaglutide or is it a class effect, tirezepatide leads to more weight loss 15% vs 12%, can we substitute mounjaro for ozempic. Also the other question comes in regards to the funding. I strongly doubt Medicare is gonna pay for a weight loss drug in a non T2DM setting (seeing they refused to publicly fund wegovy/zepbound)
Oooo not sure I’m only aware of this phase 3 trial in semeglutide specifically but please let me know if u come across others :)